Invivyd’s (IVVD) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Invivyd Trading Down 28.7 %

Shares of NASDAQ:IVVD opened at $0.92 on Tuesday. Invivyd has a 1-year low of $0.84 and a 1-year high of $5.20. The stock has a market cap of $109.78 million, a PE ratio of -0.49 and a beta of 0.66. The stock’s fifty day simple moving average is $1.15 and its two-hundred day simple moving average is $2.32.

Institutional Investors Weigh In On Invivyd

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in shares of Invivyd during the 1st quarter valued at $56,000. Tidal Investments LLC purchased a new stake in shares of Invivyd during the 1st quarter valued at $126,000. XTX Topco Ltd increased its position in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after purchasing an additional 15,376 shares during the last quarter. Chase Investment Counsel Corp purchased a new stake in shares of Invivyd during the 1st quarter valued at $271,000. Finally, Cornercap Investment Counsel Inc. purchased a new stake in shares of Invivyd during the 2nd quarter valued at $86,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.